PHILADELPHIA –– ERT, a leading global provider of high-quality patient safety and efficacy endpoint data collection, cloud analytics and workflow solutions, today announced the addition of Site Selection Analytics within the ERT Insights Cloud. Site Selection Analytics joins the Insights Cloud™ suite of data analytics, visualization and workflow applications that examine real-time clinical data and deliver actionable insights and process optimization to pharmaceutical companies and Clinical Research Organizations (CROs).
ERT’s Site Selection Analytics is available to deliver data on over 40,000 sites and millions of trial endpoints to provide sponsors and CROs with an industry-unique set of data to complement their investigational site evaluation process. Through an intuitive cloud-based interface, users can set search criteria based on geographic location, therapeutic area, indication, study phase, patient population and site activity– and then filter data over configurable periods of time to evaluate relative performance on certain behavioral and performance criteria set by ERT. Reports are generated based on filtered criteria to deliver targeted site analysis, assisting sponsors and CROs to identify sites for inclusion in clinical trials. With site inefficiencies responsible for an estimated 45% of study delays, ERT’s Site Selection Analytics provides critical insights for assessing sites’ relative performance on collecting data endpoints.
“ERT’s Site Selection Analytics offers exclusive quality data metrics on millions of ECGs, spirometry and electronic Clinical Outcome Assessment (eCOA) data endpoints,” says Amy Furlong, Executive Vice President, Cardiac Safety and eClinical Insights Solutions, ERT, “While there is a great deal of information in the public domain on patient enrollment trends, ERT’s Site Selection Analytics is uniquely situated to supplement these data points with real-time indicators of site performance based on the quality of collected endpoints.”
Site Selection is the latest addition to the ERT Insights Cloud, a first-in-class solution that is changing the paradigm of clinical trials software by offering technology-agnostic integration and automated data harmonization through its cloud-based data hub, EXPERT® Central. This software as a service (SaaS) offering coalesces enterprise-wide data sources and applies configurable analytical algorithms to gain unique insights on actionable risk and relative performance trends.
“With Site Selection Analytics, ERT is continuing to build on its vision for Insights Cloud, empowering our customers with real-time actionable insight,” continued Furlong. “With over 40 years of experience working with investigator sites, collecting millions of endpoints and delivering high quality endpoint data, ERT is uniquely positioned to deliver the business analytics our customers need to gain operational efficiencies so they can dramatically reduce trial costs and improve the quality of their clinical trials.”
ERT will demonstrate Site Selection Analytics and many other original products at its Innovation Lab Booth #2000 and also at the expanded ERT Booth #2025 during the Drug Information Association (DIA) Annual Meeting in Washington, DC beginning June 15, 2015. For more information, visit http://www/ert.com/dia-annual-meeting.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.